Table of Contents
Volume 7 | Supplement 4
Publication Date: April 2007- Abstract
- No Access
- Pay-Per View
- Full Text
- Add to Cart
Contribution | ||
S138 |
Novel Approaches to Myeloma Therapy: The Role of Newer Anthracycline-Containing Regimens Brian G. M. Durie |
|
S139-S144 |
Current Treatment Strategies for Multiple Myeloma Sheeba Thomas, Raymond Alexanian |
|
S145-S149 |
Preclinical Rationale, Mechanisms of Action, and Clinical Activity of Anthracyclines in Myeloma Mohamad A. Hussein |
|
S150-S155 |
Clinical Benefits and Economic Analysis of Pegylated Liposomal Doxorubicin/Vincristine/Dexamethasone Versus Doxorubicin/Vincristine/Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Christopher A. Porter, Robert M. Rifkin |
|
S156-S162 |
Emerging Data on the Use of Anthracyclines in Combination with Bortezomib in Multiple Myeloma Peter M. Voorhees, Robert Z. Orlowski |
|
S163-S169 |
Pegylated Liposomal Doxorubicin and Immunomodulatory Drug Combinations in Multiple Myeloma: Rationale and Clinical Experience Asher Alban Chanan-Khan, Kelvin Lee |
|
S170-S174 |
Individualizing Therapy Using Molecular Markers in Multiple Myeloma P. Leif Bergsagel |
|